Planned research includes but is not limited to whole exome sequencing, RNA SEQ and liquid biopsy assessments in substantial subsets of patients in order to help gain a deeper understanding of tumor biology and mechanisms of resistance. By building large cohorts of patients through extensive genomic analysis and more detailed clinical outcomes follow up, it will also be possible to use these cohorts as future development and validation sets for more complex predictive algorithms that may improve selection of patients for different treatments.

​

We are also planning a number of outcome analyses of the current LC-SCRUM database with the aim to provide real-world data in Asian patients, to improve the quality of care and to gain better understanding of how to best treat patients who are underrepresented in clinical trials.